1. Fink M. Treating neuroleptic malignant syndrome as catatonia. J Clin Psychopharmacol 2001;21:121-122. PMID:
11199941.
2. Paparrigopoulos T, Tzavellas E, Ferentinos P, Mourikis I, Liappas J. Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine. World J Biol Psychiatry 2009;10:70-73. PMID:
19673089.
3. Peralta V, Cuesta MJ, Serrano JF, Mata I. The Kahlbaum syndrome: a study of its clinical validity, nosological status, and relationship with schizophrenia and mood disorder. Compr Psychiatry 1997;38:61-67. PMID:
8980874.
4. Northoff G. What catatonia can tell us about "top-down modulation": a neuropsychiatric hypothesis. Behav Brain Sci 2002;25:555-577. PMID:
12958742.
5. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993;77:185-202. PMID:
8093494.
6. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998;155:1113-1116. PMID:
9699705.
7. Mann SC, Caroff SN, Fricchione G, Campbell EC. Central dopamine hypoactivity and the pathogenesis of the neuroleptic malignant syndrome. Psychiatr Ann 2000;30:363-374.
8. White DA. Catatonia and the neuroleptic malignant syndrome--a single entity? Br J Psychiatry 1992;161:558-560. PMID:
1393347.
9. White DA, Robins AH. Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry 1991;158:419-421. PMID:
1674666.
10. Raja M, Altavista MC, Cavallari S, Lubich L. Neuroleptic malignant syndrome and catatonia. A report of three cases. Eur Arch Psychiatry Clin Neurosci 1994;243:299-303. PMID:
7913834.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. 2000,Washington, DC: American Psychiatric Press.
12. Dhossche DM, Carroll BT, Carroll TD. In: Dhossche D, Wing L, Ohta M, Neumarker KIs there a Common Neuronal Basis for Autism and Catatonia? , editor. Catatonia in Autism Spectrum Disorders. 2006,St. Louis, MO: Elsevier/Academic Press, Inc.
13. Woodbury MM, Woodbury MA. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 1992;31:1161-1164. PMID:
1429421.
14. Tsai JH, Yang P, Yen JY, Chen CC, Yang MJ. Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. Pharmacotherapy 2005;25:1156-1159. PMID:
16207109.
15. Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol 2004;19:351-353. PMID:
15486522.
16. Leibold J, Patel V, Hasan RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther 2004;26:1105-1108. PMID:
15336475.
17. Zalsman G, Lewis R, Konas S, Loebstein O, Goldberg P, Burguillo F, et al. Atypical neuroleptic malignant syndrome associated with risperidone treatment in two adolescents. Int J Adolesc Med Health 2004;16:179-182. PMID:
15266995.
18. Dew RE, Rosenquist PB, McCall WV. Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome. Int J Adolesc Med Health 2005;17:187-188. PMID:
15971738.
19. Kobayashi A, Kawanishi C, Matsumura T, Kato D, Furukawa R, Kishida I, et al. Quetiapine-induced neuroleptic malignant syndrome in dementia with Lewy bodies: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1170-1172. PMID:
16682107.
20. Norgard NB, Stark JE. Olanzapine-associated neuroleptic malignant syndrome. Pharmacotherapy 2006;26:1180-1182. PMID:
16863495.
21. Nopoulos P, Flaum M, Miller DD. Atypical neuroleptic malignant syndrome (NMS) with an atypical neuroleptic: clozapine-induced NMS without rigidity. Ann Clin Psychiatry 1990;2:251-253.
22. Lee JW. Catatonic variants, hyperthermic extrapyramidal reactions, and subtypes of neuroleptic malignant syndrome. Ann Clin Psychiatry 2007;19:9-16. PMID:
17453656.
23. Fink M. Neuroleptic malignant syndrome and catatonia: one entity or two. Biol Psychiatry 1996;39:1-4. PMID:
8719118.
24. Carroll BT, Taylor RE. The nondichotomy between lethal catatonia and neuroleptic malignant syndrome. J Clin Psychopharmacol 1997;17:235-238. PMID:
9169979.
25. Carroll BT, Goforth HW. Serum iron in catatonia. Biol Psychiatry 1995;38:776-777. PMID:
8580236.
26. Nisijima K, Ishiguro T. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. J Psychiatr Res 1995;29:233-244. PMID:
7473299.
27. Northoff G, Wenke J, Pflug B. Increase of serum creatine phosphokinase in catatonia: an investigation in 32 acute catatonic patients. Psychol Med 1996;26:547-553. PMID:
8733213.
28. Northoff G, Pfennig A, Krug M, Danos P, Leschinger A, Schwarz A, et al. Delayed onset of late movement-related cortical potentials and abnormal response to lorazepam in catatonia. Schizophr Res 2000;44:193-211. PMID:
10962222.
29. Lew TY, Tollefson G. Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. Biol Psychiatry 1983;18:1441-1446. PMID:
6661471.
30. Kontaxakis VP, Christodoulou GN, Markidis MP, Havaki-Kontaxaki BJ. Treatment of a mild form of neuroleptic malignant syndrome with oral diazepam. Acta Psychiatr Scand 1988;78:396-398. PMID:
3195360.
31. Miyaoka H, Shishikura K, Otsubo T, Muramatsu D, Kamijima K. Diazepam-responsive neuroleptic malignant syndrome: a diagnostic subtype? Am J Psychiatry 1997;154:882PMID:
9167524.
32. Koch M, Chandragiri S, Rizvi S, Petrides G, Francis A. Catatonic signs in neuroleptic malignant syndrome. Compr Psychiatry 2000;41:73-75. PMID:
10646623.
33. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987;22:1004-1020. PMID:
2886157.
34. Mathews T, Aderibigbe YA. Proposed research diagnostic criteria for neuroleptic malignant syndrome. Int J Neuropsychopharmacol 1999;2:129-144. PMID:
11281981.
35. Carroll BT, Lee JW. Catatonia is a risk factor for neuroleptic malignant syndrome. J Clin Psychiatry 2004;65:1722-1723. PMID:
15641881.
36. Malur C, Pasol E, Francis A. ECT for prolonged catatonia. J ECT 2001;17:55-59. PMID:
11281518.